Ampio Pharmaceuticals, Inc. (AMPE)

-0.009 (-4.96%)
At close: May 25, 2022 4:00 PM
-0.013 (-7.975%)
Pre-market:May 26, 2022 4:20 AM EDT

Company Description

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States.

Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19.

The company is headquartered in Englewood, Colorado.

Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals Logo
CountryUnited States
SectorHealth Care
CEOMichael Macaluso

Contact Details

373 Inverness Pkwy Ste 200
Englewood, Colorado 80112-5898
United States
Phone720 437 6500

Stock Details

Ticker SymbolAMPE
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001411906

Key Executives

Michael A. MartinoChief Executive Officer and Chairman
Holli CherevkaPresident and Chief Operating Officer
Daniel G. Stokely CPA, CPAChief Financial Officer, Corporate Secretary and Treasurer
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D.Chief Medical Officer
Lane HapkeVice President of Manufacturing Operations
April RamirezClinical Trial Manager
Laura GoldbergVice President of Quality and Regulatory Operations

Latest SEC Filings

May 16, 202210-QQuarterly report [Sections 13 or 15(d)]
May 16, 20228-KCurrent report
May 2, 202210-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]
Apr 29, 2022SC 13G/AStatement of acquisition of beneficial ownership by individuals
Apr 28, 20228-KCurrent report
Apr 20, 20228-KCurrent report
Mar 29, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Mar 29, 20228-KCurrent report
Mar 2, 20228-KCurrent report
Mar 2, 20224Statement of changes in beneficial ownership of securities
View All SEC Filings